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Aim: We have assessed the risk factors for mortality and morbidity subsequent to D2-gastrectomy in
gastric cancer cases.
Patients and method: The records (age, gender, comorbidity, ASA score, POSSUM score, type of gastrec-
tomy, additional organ resection and pathologic TNM stage) were reviewed in 49 cases of D2 gastrec-
tomies (between 2003 and 2008) retrospectively.
Results: Mean age was 60.4 (range: 35e82). The factors of comorbidity (n¼ 38) in 27 patients. The
average quantity of lymph nodes was 21.2 (range: 16e31) in D2 dissections.
The rate of mortality was 8.2% (4/49). All the patients who died had major comorbid diseases and all
were submitted to total gastrectomy. Twenty-one morbidities were detected in 13 patients [morbidity
rate was 26.5% (13/49)]. We have observed a nearly statistically signiﬁcant (p¼ 0.074) disadvantage of
total gastrectomy versus subtotal gastrectomy [those who died had undergone total gastrectomy, and the
morbidity rates were 36.4% vs 14.8%] in concordance with literature.
Conclusion: In these studies, we have observed that our mortality (8.2%) and morbidity (26.5%) rates are
in concordance with the data from medical literature, and POSSUM scores are the only parameter in
positive statistical correlation with mortality. Preoperative and postoperative resuscitation are of great
importance if the patients have POSSUM score >20.
 2010 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Surgical approach to gastric cancer varies considerably around
the world. Recently a Cochrane review concluded that “randomised
studies show no evidence of overall survival beneﬁt” after D2
dissection, “but possible beneﬁt in T3þ tumors. These results may
be confounded by surgical learning curves and poor surgeon
compliance”.1
Short-term results of surgery for gastric cancer vary remarkably
between Japan and Europe.
For instance postoperative mortality after extended lymphade-
nectomy (D2) was 0.8% or even absent in randomized trials from
East Asia, and less than 2% in the Japanese nationwide registry.
However, it increased to 2e5% in Western observational studies or
a phase II trial (3.1%), and peaked at up to 5e13% in European
clinical trials. Similar differences were observed as regards post-
operative morbidity after extended lymphadenectomy, which was
again lowest (17e21%) in East Asian trials, intermediate (21e35%)a Hastanesi, 1.Genel Cerrahi
: þ90 5324263515.
soy).
ciates Ltd. Published by Elsevier Ltin European observational studies or phase II trial, and the highest
in European phase III trials (43e46%).1
In order to contribute to the deﬁnition of surgical quality
criteria, we reviewed short-term results of surgery for gastric
cancer in our study.2. Patients and method
The study was a retrospective follow-up a cohort of patients
with gastric cancer (without distant metastasis) between January
2003 and October 2008.
Preoperatively, all patients underwent esophago-gastro-duo-
denoscopy with biopsies and histopathologic examination. In
addition, CT-scans were done to look for evidence of metastases.
A total of 65 patients with gastric cancer (without distant
metastasis) were operated on.
Sixteen patients with non-standard gastric operation (6 explor-
ative laparotomies, 6 non-standard gastrectomies and 4 palliative
gastroenterostomies) were excluded from the study.
The patients who were performed an en bloc resection of the
stomach with extended D2-lymphadenectomy were selected ford. All rights reserved.
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<50 (n¼ 10) (20.4%) n¼ 0 n¼ 2 (20%)
50e69 (n¼ 31) (63.3%) n¼ 2 (6.5%) 0.51 n¼ 8 (25.8%) 0.94
>70 (n¼ 8) (16.3%) n¼ 2 (25%) NS n¼ 3 (37.5%) NS
(2) Gender
Male (n¼ 34) (69.4%) n¼ 4 (11.8%) 0.41 n¼ 7 (20.6%) 0.29
Female (n¼ 15) (30.6%) n¼ 0 NS n¼ 6 (40%) NS
(3) Comorbidity
0 Factor (n¼ 22) (44.9%) n¼ 1 (4.5%) n¼ 4 (18.2%)
1 Factor (n¼ 17) (34.7%) n¼ 2 (11.8%) 0.48 n¼ 5 (29.4%) 0.70
2 Factors (n¼ 9) (18.4%) n¼ 1 (11.1%) NS n¼ 4 (44.4%) NS
3 Factors (n¼ 1) (2%) n¼ 0 n¼ 0
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I (No. 1e6) and II (No. 7e12).
The records (age, gender, comorbidity, ASA score, POSSUM score
(Physiologic and Operative Severity Score for the enUmeration of
Mortality and Morbidity), type of gastrectomy, additional organ
resection and pathologic TNM stage) were reviewed in the 49 D2
gastrectomies retrospectively.
POSSUM was measured on a calculation sheet (website: http://
www.sfar.org/scores2/possum2.html).
All operations were performed after treating comorbid condi-
tions as much as possible.
Operative mortality and morbidity were deﬁned as death or
complications occurred within 30 days after the operation.
Statistical analysis was performed, using SPSS version 10.0 and
p< 0.05 values were considered statistically signiﬁcant.(4) ASA score
ASA 1 (n¼ 29) (59.2%) n¼ 1 (3.4%) n¼ 5 (17.2%)
ASA 2 (n¼ 11) (22.4%) n¼ 1 (9.1%) 0.50 n¼ 4 (36.4%) 0.42
ASA 3 (n¼ 9) (18.4%) n¼ 2 (22.2%) NS n¼ 4 (44.4%) NS
(5) POSSUM score
11e14 (n¼ 23) (46.9%) n¼ 0 n¼ 3 (13%)
15e20 (n¼ 20) (40.8%) n¼ 1 (5%) 0.0064 n¼ 7 (35%) 0.28
21e30 (n¼ 6) (12.2%) n¼ 3 (50%) n¼ 3 (50%) NS
(6) Gastrectomy
Total (n¼ 22) (44.9%) n¼ 4 (18.2%) 0.074 n¼ 8 (36.4%) 0.16
Subtotal (n¼ 27) (55.1%) n¼ 0 NS n¼ 4 (14.8%) NS
(7) Additional organ
Splenectomy (n¼ 4) (8.2%) n¼ 0 # n¼ 2 (50%)
Liver (n¼ 1) (2%) n¼ 0 n¼ 0 0.84
Gallbladder (n¼ 1) (2%) n¼ 0 n¼ 0 NS
Colon (n¼ 1) (2%) n¼ 0 n¼ 0
(8) Stage (pTNM)
Ia (n¼ 5) (10.2%) n¼ 1 (20%) n¼ 0
Ib (n¼ 3) (6.1%) n¼ 0 n¼ 1 (33.3%)
II (n¼ 15) (30.6%) n¼ 2 (13.3%) 0.90 n¼ 5 (33.3%) 0.95
IIIa (n¼ 12) (24.5%) n¼ 0 NS n¼ 4 (33.3%) NS
IIIb (n¼ 12) (24.5%) n¼ 1 (8.3%) n¼ 2 (16.7%)
IV (T4N2) (n¼ 2) (4.1%) n¼ 0 n¼ 1 (50%)
NS: not signiﬁcant; #: not appropriate for statistics. bold/underlined: only signiﬁ-
cant difference; underlined: nearly signiﬁcant difference but not signiﬁcant.3. Results
Mean age was 60.4 (range: 35e82). The factors of comorbidity
(n¼ 38) in the 27 patients were hypertension (n¼ 12), diabetes
mellitus (n¼ 8), chronic obstructive pulmonary disease (n¼ 7),
chronic cardiac failure (n¼ 5), coronary artery disease (n¼ 4),
sinusoidal tachycardia (n¼ 1), pulmonary histocytosis-X (n¼ 1).
The pathologic TNM stages of the patients are shown in Table 1.
The average quantity of lymph nodes was 21.2 (range: 16e31) in
the D2 dissections.
Mortality rate was 8.2% (4/49). All the patients who died had
major comorbidity and all were submitted to total gastrectomy; one
of those had pulmonary histocytosis-X and died in postoperative
period due to ARDS. The second one hospitalised before the gastric
operation with serious gastric bleeding; after a transfusion with 8
erythrocytes suspension he was operated but postoperatively he
died because of anastomosis failure and septic shock. The third
patient had hypertension as comorbidity, and despite preoperative
stabilization a malign hypertension was developed preoperatively
and the patient died because of cerebrovascular bleeding. The fourth
patient was malnutrised due to gastric outlet syndrome and died
postoperatively because of ARDS.
Morbidity rate was 26.5% (13/49). Twenty-one morbidity
[wound infection (n¼ 6), pulmonary infection (n¼ 4), atrial ﬁbri-
lation (n¼ 4), pulmonary embolism (n¼ 2), intraabdominal abscess
(n¼ 2), diabetic ketoacidosis (n¼ 1), intraabdominal hemorrhage
(n¼ 1) and the syndrome of inappropriate antidiuretic hormone
secretion (n¼ 1)] were detected in the 13 patients.
The statistics of the parameters according to mortality and
morbidity are shown in Table 2.4. Discussion
Although morbidity and mortality rates of gastrectomy for
gastric cancer were different, in a data analysis of 22 cancer centers
the mortality rate was reported between 3.1% and 31%.2 Our
mortality rate of 8.2% is in agreement with literature reports; theTable 1
The pathologic TNM stages of the patients.
pTNM M0 M1
N0 (n¼ 12) N1 (n¼ 19) N2 (n¼ 18)
M0 T1 (n¼ 11) IA (n¼ 5) IB (n¼ 2) II (n¼ 4) IV
T2 (n¼ 14) IB (n¼ 1) II (n¼ 7) IIIA (n¼ 6)
T3 (n¼ 14) II (n¼ 4) IIIA (n¼ 4) IIIB (n¼ 6)
T4 (n¼ 10) IIIA (n¼ 2) IIIB (n¼ 6) IV (n¼ 2)
M1 IVmorbidity rate of 26.5% is in concordance with the data of literature
in which the morbidity has been reported as being 8e31%.3,4
Various studies5,6 have demonstrated that the morbidity
increased with age but no signiﬁcant correlation was found;
however other studies emphasized that the age is a predictor factor
of morbidity.7,8 In our experience patients over 50 years old had an
increased mortality rate, and the morbidity increased with age but
no signiﬁcant correlation was found.
The gender, independently or in correlation with other factors
have negative inﬂuence on morbidity5,6,8,9; in the current study we
found thatmale gender negatively affected postoperativemortality,
however the morbidity was found higher for female gender (20.6%
vs 40%).
The preexisting multiple medical illnesses (comorbidity)
involved a higher morbidity and mortality rate.6,9Our results indi-
cate that the number of comorbidities is correlated with morbidity
(one comorbid factor was associated with 29.4%, two comorbid
factors present was associated with 44.4% morbidity) but no
correlation was found with mortality.
Our study results conclude similarly tomost of those reported in
literature, that the ASA score is not predictive for mortality and
morbidity.5,7
The POSSUM score is used to predict the postoperative course of
patients with gastric carcinoma undergoing D2-lymphadenec-
tomy6,10,11; Luna et al. showed that the POSSUM and O-POSSUM
overestimate, and P-POSSUM underestimate the postoperative
F.N. Koksoy et al. / International Journal of Surgery 8 (2010) 633e635 635mortality.11 In the study of Bollschweiler10 the calculated POSSUM
overestimated the risk of developing postoperative complications.
Despite that the authors prefer to use this instrument; in our study
was the only parameter in positive statistical correlation with
mortality (p¼ 0.0064). On the other hand, the POSSUM Score was
correlated with morbidity (11e14 scores: 13%; 15e20 scores: 35%;
21e30 scores: 50%).
An increasing number of units in North America and Europe are
identifying the beneﬁts of preoperative and perioperative resusci-
tation to high-risk patients and the POSSUM system can allow for
changes over time in our medical treatment.12
We have observed a nearly statistically signiﬁcant (p¼ 0.074)
disadvantage of total gastrectomy versus subtotal gastrectomy [the
patients who died had undergone total gastrectomy, and the
morbidity rates were 36.4% vs 14.8%] in concordance with
literature.5,7
Additional organ resection was associated with high mortality
and morbidity rates.5e9 In our study, two of four splenectomized
patients have complications in their postoperative course.
The pTNM-stage of gastric cancer was not predictive for
mortality and morbidity in our study.
In this study, we have observed that our mortality (8.2%) and
morbidity (26.5%) rates are in concordance with the data of liter-
ature, and POSSUM scores are the only parameter in positive
statistical correlation with mortality. Additionally, if POSSUM
score >15 postoperative morbidity moves higher (35%) and if
score >20 postoperative morbidity and mortality increase. Espe-
cially in the patients who have POSSUM score >20 preoperative
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